The Interaction of Immobilized Thrombin with Human Antithrombin III

Summary

Interaction of human antithrombin III (AT III) with human α-thrombin coupled to Sepharose 4B was investigated. Despite markedly reduced esterolytic, amidolytic and especially coagulant activity, more than 90% of immobilized thrombin formed stable complexes with purified AT III. Presence of high affinity heparin did not facilitate the inhibition to the degree seen in reactions conducted with soluble thrombin. Instead, heparin induced proteolysis of up to 66% of the inhibitor that remained in solution. This led to the isolation of a homogeneous protein fragment which migrated in SDS-gel electrophoresis as a band of 50,000 Mr, cross-reacted with antibodies to human AT III but showed no biologic activity nor sufficient affinity for heparin. Out of the three major inhibitors capable of binding soluble thrombin in human plasma, only AT III reacted with immobilized thrombin. However, Sepharose-coupled thrombin mixed with plasma in the presence of heparin produced outstanding quantities of residual immunoreactive AT III devoid of inhibitory activity. These data suggest that presence of high affinity heparin in the environment of thrombin attached to a solid support may dramatically decrease the efficiency of enzyme inhibition.

Key Words

Antithrombin III - Immobilized thrombin - Heparin

• References

• 1 Abildgaard U. Evidence that antithrombin III is the main inhibitor of coagulation enzymes. In: The Physiological Inhibitors of Blood Coagulation and Fibrynolysis. Collen D, Wiman B, Verstraete M. (Eds) Elsevier; North HoUand, Amsterdam: 1979. pp 31-33
• 2 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505
• 3 Marciniak E. Thrombin-induced proteolysis of human antithrombin III: an outstanding contribution of heparin. Br J Haematol 1981; 48: 325-336
• 4 Marciniak E. Differential role of fractionated heparin in antithrombin- III proteolysis. Blood 1982; 59: 576-581
• 5 Marciniak E, Gora-Maslak G. Enhancement by heparin of thrombin- induced antithrombin III proteolysis: its relation to the molecular weight and anticoagulant activity of heparin. Thromb Res 1982; 28: 411-421
• 6 Bjork I, Fish WW. Production in vitro and properties of the modified form of bovine antithrombin, cleaved at the active site by thrombin. J Biol Chem 1982; 257: 9487-9493
• 7 Marciniak E, Gora-Maslak G. High molecular weight forms of antithrombin III complexes in blood. Thromb Haemostas 1983; 49: 32-36
• 8 Thaler E, Schmer G. A simple two-step isolation procedure for human and bovine antithrombin II/III (heparin cofactor): a comparison of two methods. Br J Haematol 1975; 31: 233-243
• 9 Marciniak E. Antithrombin III and heparin inactivation in thrombin involving reactions. Thromb Haemostas 1977; 38: 486-493
• 10 Laurell CB. Quantitative estimation of proteins in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
• 11 Sas G, Pepper DS, Cash JD. Plasma and serum antithrombin III: differentiation by crossed immunoelectrophoresis. Thromb Res 1975; 6: 87-91
• 12 Hunter MW. Radioimmunoassay. In: Handbook of Experimental Immunology. Weir DM. (Ed) Blackwell Scientific Publications, Oxford; 1967. pp 17.1-17.36
• 13 Fenton JW, Fasco JJ, Stackrow AB, Aronson DL, Young AM, Finlayson JS. Human thrombins. Production, evaluation and properties of α-thrombin. J Biol Chem 1977; 252: 3587-3598
• 14 Cuatrecasas P, Wilchek M, Anfinsen CB. Selective enzyme purification by affinity chromatography. Proc Nat Acad Sci USA 1968; 61: 636-643
• 15 Hummel BC W. A modified spectrophotometric determination of chymotrypsin, trypsin and thrombin. Can J Biochem Physiol 1959; 37: 1393-1399
• 16 Brosstad F. Purification, characterization and insolubilization of bovine thrombin. Thromb Res 1977; 11: 119-130
• 17 Pye EK, Chance B. Investigation of the physical properties of immobilized enzymes. In: Methods of Enzymology. Mosbach K. (Ed) Academic Press; New York: 1976. 44 357-372
• 18 Goldstein L. Kinetic behavior of immobilized enzymes. In: Methods in Enzymology. Mosbach K. (Ed) Academic Press; New York: 1976. 44 397-443
• 19 Blow DM. The structure of chymotrypsin. In: The Enzymes. Boyer PD. (Ed) Academic Press; New York: 1971. 3 185-212
• 20 Haynes R, Walsh KA. Enzyme envelopes on colloidal particles. Biochem Biophys Res Commun 1969; 36: 235-242
• 21 Glassmeyer CK, Ogle JD. Properties of insoluble form of trypsin. Biochemistry 1971; 10: 786-792
• 22 Laurent TC, Tengblad A, Thunberg L, Hook M, Lindahl U. The molecular weight dependence of the anti-coagulant activity of heparin. Biochem J 1978; 175: 691-701
• 23 Lindahl U, Backstrom G, Hook M, Thunberg L, Fransson LA, Linker A. Structure of the antithrombin binding site in heparin. Proc Nat Acad Sci USA 1979; 76: 3198-3202
• 24 Ganguly P. Binding of thrombin to human platelets. Nature 1974; 247: 306-307
• 25 Awbrey BJ, Hoak JC, Owen WG. Binding of human thrombin to cultured human endothelial cells. J Biol Chem 1979; 254: 4092-4095
• 26 Baker JB, Low DA, Simmer RL, Cunningham DD. Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 1980; 21: 37-45
• 27 Lollar P, Owen WG. Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. J Clin Invest 1980; 66: 1222-1230
• 28 Busch C, Owen WG. Identification in vitro of an endothelial cell surface cofactor for antithrombin III. J Clin Invest 1982; 69: 726-729